Former FDA Commissioners Endorse Heidi Overton as Strong Choice to Lead Agency

Two former FDA commissioners, Scott Gottlieb and Mark B. McClellan, wrote an opinion piece supporting Heidi Overton’s nomination to lead the agency. They note her confirmation hearing is set before the Senate health committee and argue she is the right choice at a critical time.

The authors point out that biomedical innovation is accelerating faster than ever, offering new ways to improve health in the United States. Overton, they say, has the experience to help translate this wave of breakthroughs into public benefit.

They also warn that the FDA’s regulatory and clinical development capacity is under strain, especially as other countries such as China expand their own biomedical enterprises. Overton’s leadership, they argue, could bridge the gap and strengthen the agency’s role.